Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00805233 · ClinicalTrials.gov registry record · Phase 2
Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration
A Phase 2 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00805233: Completed Phase 2 study, sponsored by Oregon Health and Science University.
NCT00805233 is a Phase 2 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00805233, a Phase 2 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This open-label, randomized, Phase II research study will look to see whether an investigational treatment combining bromfenac ophthalmic drops with ranibizumab intravitreal injection is safe and effective for treating wet AMD as compared to ranibizumab alone.
Interventions
- DRUG combination ranibizumab + bromfenac
- DRUG ranibizumab injection alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
What the finished NCT00805233 record still lists
NCT00805233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which combination ranibizumab + bromfenac is the first listed.
NCT00805233 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00805233 about?
NCT00805233 is a clinical study titled "Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration". This open-label, randomized, Phase II research study will look to see whether an investigational treatment combining bromfenac ophthalmic drops with ranibizumab intravitreal injection is safe and effective for treating wet AMD as compared to ranibizumab alone.
What is the current status of trial NCT00805233?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2008-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00805233?
The interventions under investigation include: combination ranibizumab + bromfenac (DRUG), ranibizumab injection alone (DRUG).
Who is sponsoring clinical trial NCT00805233?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00805233's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia